

Alexandra Borodovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10993009/publications.pdf>

Version: 2024-02-01

15
papers

1,040
citations

933264

10
h-index

1125617

13
g-index

15
all docs

15
docs citations

15
times ranked

2004
citing authors

#	ARTICLE	IF	CITATIONS
1	Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothed Antagonists. <i>Cancer Cell</i> , 2013, 23, 23-34.	7.7	296
2	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <i>Oncotarget</i> , 2013, 4, 1729-1736.	0.8	213
3	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. <i>Oncotarget</i> , 2013, 4, 1737-1747.	0.8	141
4	Repurposing the Antihelminthic Mebendazole as a Hedgehog Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 3-13.	1.9	78
5	Small molecule AZD4635 inhibitor of A _{2A} R signaling rescues immune cell function including CD103 ⁺ dendritic cells enhancing anti-tumor immunity. , 2020, 8, e000417.		65
6	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. <i>Clinical Cancer Research</i> , 2020, 26, 2176-2187.	3.2	54
7	Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. <i>Current Opinion in Oncology</i> , 2012, 24, 83-89.	1.1	52
8	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. <i>Neuro-Oncology</i> , 2019, 21, 189-200.	0.6	49
9	Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. <i>Oncotarget</i> , 2017, 8, 80124-80138.	0.8	33
10	Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization. <i>Analytical Biochemistry</i> , 2019, 568, 78-88.	1.1	22
11	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. <i>Journal of Neuro-Oncology</i> , 2015, 121, 479-487.	1.4	14
12	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model. <i>Frontiers in Immunology</i> , 2021, 12, 617316.	2.2	10
13	Abstract 3751: Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models. <i>Cancer Research</i> , 2018, 78, 3751-3751.	0.4	8
14	A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity. <i>British Journal of Pharmacology</i> , 2021, 178, 600-613.	2.7	5
15	ET-08 * DEMETHYLATING THERAPY INDUCES DIFFERENTIATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v80-v80.	0.6	0